FLAIR: A trial of ibrutinib with rituximab for chronic lymphocytic leukaemia
Principal Investigator: Dr Kathryn Goddard Sponsor: University of Leeds This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL). |
DLBCL: A trial of ibrutinib with chemotherapy and rituximab for a type of diffuse large B cell lymphoma (PHOENIX)
Principal Investigator: Dr Arun Alfred Sponsor: Celltrion Inc. This trial is looking at a drug called ibrutinib for a type of non Hodgkin lymphoma called diffuse large B cell lymphoma (DLBCL). It is for people who have a particular type of DLBCL and who haven’t had any other treatment for their lymphoma. |
MYELOMA XI
Principal Investigator: Dr Arun Alfred Sponsor: University of Leeds This trial looked at lenalidomide, carfilzomib, bortezomib and vorinostat for people having intensive treatment for newly diagnosed myeloma. |